Dr. Rini on the Axitinib and Sorafenib Trial VEGF Focus

onclivetv has 407 videos Subscribe Here

Description: Lead investigator Brian I. Rini, MD, a staff member in the Department of Solid Tumor Oncology at the Taussig Cancer Institute at Cleveland Clinic in Ohio, explains the vascular enthothelial growth factor (VEGF) potency and comparison explored in the AXIS 1032 phase III trial comparing axitinib to sorafenib (both VEGF inhibitors) in the second-line setting for metastatic renal cell carcinoma (mRCC).
Shared By : onclivetv
Posted on : 07/01/11
Added : 6 years ago
Category :

More From onclivetv

Nothing found.